SML0603
Lixivaptan
≥96% (HPLC)
别名:
N-[3-Chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepine-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methylbenzamide, VPA 985, WAY-VPA 985
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
Assay:
≥96% (HPLC)
Form:
powder
description
4% w/w in ethyl acetate
assay
≥96% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
room temp
SMILES string
Fc1cc(c(cc1)C)C(=O)Nc2cc(c(cc2)C(=O)N3Cc4[n](ccc4)Cc5c3cccc5)Cl
InChI
1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33)
InChI key
PPHTXRNHTVLQED-UHFFFAOYSA-N
Biochem/physiol Actions
Arginine vasopressin (AVP) plays an important part in circulatory and water homoeostasis and is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). Lixivaptan is an AVP V2-receptor selective antagonist that increases water excretion and normalizes serum sodium levels. Lixivaptan has been in clinical trials for hyponatremia associated with heart failure.
Lixivaptan is an arginine vasopressin (AVP) V2-receptor antagonist.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable